Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials
Top Cited Papers
- 23 November 2004
- Vol. 329 (7478) , 1317
- https://doi.org/10.1136/bmj.38273.626655.63
Abstract
Objective To estimate the analgesic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase-2 inhibitors (coxibs), in patients with osteoarthritis of the knee. Design Systematic review and meta-analysis of randomised placebo controlled trials. Studies reviewed 23 trials including 10 845 patients, median age of 62.5 years. 7807 patients received adequate doses of NSAIDs and 3038 received placebo. The mean weighted baseline pain score was 64.2 mm on 100 mm visual analogue scale (VAS), and average duration of symptoms was 8.2 years. Main outcome measure Change in overall intensity of pain. Results Methodological quality of trials was acceptable, but 13 trials excluded patients before randomisation if they did not respond to NSAIDs. One trial provided long term data for pain that showed no significant effect of NSAIDs compared with placebo at one to four years. The pooled difference for pain on visual analogue scale in all included trials was 10.1 mm (95% confidence interval 7.4 to 12.8) or 15.6% better than placebo after 2-13 weeks. The results were heterogeneous, and the effect size for pain reduction was 0.32 (0.24 to 0.39) in a random effects model. In 10 trials that did not exclude non-responders to NSAID treatment the results were homogeneous, with an effect size for pain reduction of 0.23 (0.15 to 0.31). Conclusion NSAIDs can reduce short term pain in osteoarthritis of the knee slightly better than placebo, but the current analysis does not support long term use of NSAIDs for this condition. As serious adverse effects are associated with oral NSAIDs, only limited use can be recommended.Keywords
This publication has 58 references indexed in Scilit:
- Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo‐controlled trialArthritis & Rheumatism, 2003
- Nonsteroidal Anti-Inflammatory Drugs and Heart FailureDrugs, 2003
- The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosisActa Orthopaedica, 2001
- Markers of cartilage and synovial metabolism in joint fluid and serum of patients with chondromalacia of the patellaOsteoarthritis and Cartilage, 1998
- NSAIDs and Increased Blood PressureDrug Safety, 1997
- A double-masked comparison of naprelan® and nabumetone in osteoarthritis of the kneeClinical Therapeutics, 1997
- The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the kneeClinical Therapeutics, 1996
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trialCurrent Medical Research and Opinion, 1989
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986